Influenza viral infection is a risk factor for severe illness in COVID-19 patients: a nationwide population-based cohort study

References

• Bresee J, Fitzner J, Campbell H, et al. Progress and remaining gaps in estimating the global disease burden of influenza. Emerg Infect Dis. 2018;24(7):1173–1177. doi:10.3201/eid2407.171270. [published Online First: 2018/06/19].
   PubMed Web of Science ®Google Scholar
• Sullivan SG, Cowling BJ. Reconciling estimates of the global influenza burden. Lancet Respir Med. 2019;7(1):8–9. doi:10.1016/S2213-2600(18)30511-3. [published Online First: 2018/12/17].
   PubMed Web of Science ®Google Scholar
• Gandhi RT, Lynch JB, Del Rio C. Mild or Moderate Covid-19. N Engl J Med. 2020;383(18):1757–1766. doi:10.1056/NEJMcp2009249. [published Online First: 2020/04/25].
   PubMed Web of Science ®Google Scholar
• Cucinotta D, Vanelli M. WHO declares COVID-19 a pandemic. Acta Biomed. 2020 Mar 19;91(1):157–160.
   PubMedGoogle Scholar
• WHO. Weekly epidemiological update on COVID-19 - 6 January 2022. https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19—6-january-2022.
   Google Scholar
• Kompaniyets L, Pennington AF, Goodman AB, et al. Underlying medical conditions and severe illness among 540,667 adults hospitalized with COVID-19, 2021. Prev Chronic Dis. 2021;18:E66, doi:10.5888/pcd18.210123. [published Online First: 2021/07/02].
   PubMed Web of Science ®Google Scholar
• Harrison SL, Fazio-Eynullayeva E, DA L, et al. Comorbidities associated with mortality in 31,461 adults with COVID-19 in the United States: a federated electronic medical record analysis. PLoS Med. 2020;17(9):e1003321, doi:10.1371/journal.pmed.1003321. [published Online First: 2020/09/11].
   PubMed Web of Science ®Google Scholar
• Emanuel EJ, Persad G, Upshur R, et al. Fair allocation of scarce medical resources in the time of COVID-19. N Engl J Med. 2020;382(21):2049–2055. doi:10.1056/NEJMsb2005114. [published Online First: 2020/03/24].
   PubMed Web of Science ®Google Scholar
• Berlin DA, Gulick RM, Martinez FJ. Severe Covid-19. N Engl J Med. 2020;383(25):2451–2460. doi:10.1056/NEJMcp2009575. [published Online First: 2020/05/16].
   PubMed Web of Science ®Google Scholar
• Zheng J, Chen F, Wu K, et al. Clinical and virological impact of single and dual infections with influenza A (H1N1) and SARS-CoV-2 in adult inpatients. PLoS Negl Trop Dis. 2021;15(11):e0009997, doi:10.1371/journal.pntd.0009997. [published Online First: 2021/11/30].
   PubMed Web of Science ®Google Scholar
• Bao L, Deng W, Qi F, et al. Sequential infection with H1N1 and SARS-CoV-2 aggravated COVID-19 pathogenesis in a mammalian model, and co-vaccination as an effective method of prevention of COVID-19 and influenza. Signal Transduct Target Ther. 2021;6(1):200, doi:10.1038/s41392-021-00618-z. [published Online First: 2021/05/22].
   PubMed Web of Science ®Google Scholar
• Zhang AJ, Lee AC, Chan JF, et al. Coinfection by severe acute respiratory syndrome coronavirus 2 and influenza A(H1N1)pdm09 virus enhances the severity of pneumonia in golden Syrian hamsters. Clin Infect Dis. 2021;72(12):e978–e992. doi:10.1093/cid/ciaa1747. [published Online First: 2020/11/21].
   PubMed Web of Science ®Google Scholar
• Yue H, Zhang M, Xing L, et al. The epidemiology and clinical characteristics of co-infection of SARS-CoV-2 and influenza viruses in patients during COVID-19 outbreak. J Med Virol. 2020;92(11):2870–2873. doi:10.1002/jmv.26163. [published Online First: 2020/06/13].
   PubMed Web of Science ®Google Scholar
• Stańczak-Mrozek KI, Sobczak A, Lipiński L, et al. The potential benefits of the influenza vaccination on COVID-19 mortality rate—a retrospective analysis of patients in poland. Vaccines (Basel). 2022;10(1):5.
   Web of Science ®Google Scholar
• Hosseini-Moghaddam SM, He S, Calzavara A, et al. Association of influenza vaccination with SARS-CoV-2 infection and associated hospitalization and mortality among patients aged 66 years or older. JAMA Netw Open. 2022;5(9):e2233730.
   PubMed Web of Science ®Google Scholar
• Guan Z, Chen C, Li Y, et al. Impact of coinfection with SARS-CoV-2 and influenza on disease severity: a systematic review and meta-analysis. Front Public Health. 2021;9:773130.
   PubMed Web of Science ®Google Scholar
• Kyoung DS, Kim HS. Understanding and utilizing claim data from the Korean national health insurance service (NHIS) and health insurance review & assessment (HIRA) database for research. J Lipid Atheroscler. 2022 May;11(2):103–110.
   PubMedGoogle Scholar
• Zhang Z, Kim HJ, Lonjon G, et al. Written on behalf of AME big-data clinical trial collaborative group. balance diagnostics after propensity score matching. Ann Transl Med. 2019 Jan;7(1):16.
   PubMed Web of Science ®Google Scholar
• VanderWeele TJ, Ding P. Sensitivity analysis in observational research: introducing the E-value. Ann Intern Med. 2017;167(4):268–274.
   PubMed Web of Science ®Google Scholar
• Peng JY, Shin DL, Li G, et al. Time-dependent viral interference between influenza virus and coronavirus in the infection of differentiated porcine airway epithelial cells. Virulence. 2021;12(1):1111–1121. doi:10.1080/21505594.2021.1911148. [published Online First: 2021/05/27].
   PubMed Web of Science ®Google Scholar
• Schweitzer KS, Crue T, Nall JM, et al. Influenza virus infection increases ACE2 expression and shedding in human small airway epithelial cells. Eur Respir J. 2021 Jul 1;58(1):2003988.
   PubMed Web of Science ®Google Scholar
• Ni W, Yang X, Yang D, et al. Role of angiotensin-converting enzyme 2 (ACE2) in COVID-19. Crit Care. 2020;24(1):422.
   PubMed Web of Science ®Google Scholar
• Zheng M. ACE2 and COVID-19 susceptibility and severity. Aging Dis. 2022 Apr 1;13(2):360–372.
   PubMed Web of Science ®Google Scholar
• Sajuthi SP, DeFord P, Li Y, et al. Type 2 and interferon inflammation regulate SARS-CoV-2 entry factor expression in the airway epithelium. Nat Commun. 2020;11(1):5139.
   PubMed Web of Science ®Google Scholar
• Wang J, Nikrad MP, Phang T, et al. Innate immune response to influenza a virus in differentiated human alveolar type II cells. Am J Respir Cell Mol Biol. 2011;45(3):582–591.
   PubMed Web of Science ®Google Scholar
• Ziegler CGK, Allon SJ, Nyquist SK, et al. SARS-CoV-2 receptor ACE2 Is an interferon-stimulated gene in human airway epithelial cells and Is detected in specific cell subsets across tissues. Cell. 2020;181(5):1016–1035.e19.
   PubMed Web of Science ®Google Scholar
• Heaton NS, Langlois RA, Sachs D, et al. Long-term survival of influenza virus infected club cells drives immunopathology. J Exp Med. 2014;211:1707–1714.
   PubMed Web of Science ®Google Scholar
• Keeler SP, Agapov EV, Hinojosa ME, et al. Influenza a virus infection causes chronic lung disease linked to sites of active viral RNA remnants. J Immunol. 2018;201(8):2354–2368.
   PubMed Web of Science ®Google Scholar
• Sun J, Madan R, Karp CL, et al. Effector T cells control lung inflammation during acute influenza virus infection by producing IL-10. Nat Med. 2009;15:277–284.
   PubMed Web of Science ®Google Scholar
• Heuberger J, Trimpert J, Vladimirova D, et al. Epithelial response to IFN-γ promotes SARS-CoV-2 infection. EMBO Mol Med. 2021 Apr 9;13(4):e13191.
   PubMed Web of Science ®Google Scholar
• Mauad T, Hajjar LA, Callegari GD, et al. Lung pathology in fatal novel human influenza a (H1N1) infection. Am J Respir Crit Care Med. 2010;181(1):72–79.
   PubMed Web of Science ®Google Scholar
• Wiley JA, Cerwenka A, Harkema JR, et al. Production of interferon-γ by influenza hemagglutinin-specific CD8 effector T cells influences the development of pulmonary immunopathology. Am J Pathol. 2001;158(1):119–130.
   PubMed Web of Science ®Google Scholar
• Hamilton JR, Sachs D, Lim JK, et al. Club cells surviving influenza A virus infection induce temporary nonspecific antiviral immunity. Proc Natl Acad Sci U S A. 2016;113:3861–3866.
   PubMed Web of Science ®Google Scholar
• Dumm RE, Fiege JK, Waring BM, et al. Non-lytic clearance of influenza B virus from infected cells preserves epithelial barrier function. Nat Commun. 2019;10:779.
   PubMed Web of Science ®Google Scholar
• Garcia GL, Valenzuela A, Manzoni T, et al. Distinct chronic post-viral lung diseases upon infection with influenza or parainfluenza viruses differentially impact superinfection outcome. Am J Pathol. 2020;190(3):543–553.
   PubMed Web of Science ®Google Scholar
• Zamorano Cuervo N, Grandvaux N. ACE2: Evidence of role as entry receptor for SARS-CoV-2 and implications in comorbidities. Elife. 2020 Nov 9;9:e61390.
   PubMed Web of Science ®Google Scholar
• Leung JM, Yang CX, Tam A. ACE-2 expression in the small airway epithelia of smokers and COPD patients: implications for COVID-19. Eur Respir J. 2020 May 14;55(5):2000688.
   PubMed Web of Science ®Google Scholar
• Bui LT, Winters NI, Chung MI, et al. Chronic lung diseases are associated with gene expression programs favoring SARS-CoV-2 entry and severity. Nat Commun. 2021;12(1):4314.
   PubMed Web of Science ®Google Scholar
• McNab F, Mayer-Barber K, Sher A, et al. Type I interferons in infectious disease. Nat Rev Immunol. 2015;15(2):87–103.
   PubMed Web of Science ®Google Scholar
• Chotpitayasunondh T, Fischer TK, Heraud JM, et al. Influenza and COVID-19: what does co-existence mean? Influenza Other Respir Viruses. 2021;15(3):407–412. doi:10.1111/irv.12824. [published Online First: 2020/11/01].
   PubMed Web of Science ®Google Scholar
• Lee H, Lee H, Song KH, et al. Impact of public health interventions on seasonal influenza activity during the COVID-19 outbreak in Korea. Clin Infect Dis. 2021;73(1):e132–e140.
   PubMed Web of Science ®Google Scholar
• Feng L, Zhang T, Wang Q, et al. Impact of COVID-19 outbreaks and interventions on influenza in China and the United States. Nat Commun. 2021;12(1):3249.
   PubMed Web of Science ®Google Scholar
• Ministry of Health and Welfare. Coronavirus (COVID-19), Republic of Korea: about COVID-19: COVID-19 response. http://ncov.mohw.go.kr/en/baroView.do?brdId=11&brdGubun=111&dataGubun=&ncvContSeq=&contSeq=&board_id=.
   Google Scholar
• Shin HS, Park H, Kwon JS, et al. National academy of medicine of Korea (NAMOK) Key statements on COVID-19. J Korean Med Sci. 2021;36(41):e287, doi:10.3346/jkms.2021.36.e287. [published Online First: 2021/10/27].
   PubMed Web of Science ®Google Scholar
• Kim YJ, Sung H, Ki CS, et al. COVID-19 testing in South Korea: current status and the need for faster diagnostics. Ann Lab Med. 2020;40(5):349–350. doi:10.3343/alm.2020.40.5.349. [published Online First: 2020/04/03].
   PubMed Web of Science ®Google Scholar
• Shin GS, Choi SE. Influenza vaccination status and influencing factors in chronic patients in Korea. Korean Public Health Res. 2020;46(3):59–74. doi:10.22900/kphr.2020.46.3.005.
   Google Scholar
• Tokars JI, Olsen SJ, Reed C. Seasonal incidence of symptomatic influenza in the United States. Clin Infect Dis. 2018;66(10):1511–1518.
   PubMed Web of Science ®Google Scholar
• Cohen C, Kleynhans J, Moyes J, et al. PHIRST Group. asymptomatic transmission and high community burden of seasonal influenza in an urban and a rural community in South Africa, 2017-18 (PHIRST): a population cohort study. Lancet Glob Health. 2021 Jun;9(6):e863–e874.
   PubMed Web of Science ®Google Scholar
• Leung NHL, Xu C, Ip DKM, et al. Review Article: The Fraction of Influenza Virus Infections That Are Asymptomatic: A Systematic Review and Meta-analysis. Epidemiology. 2015;26(6):862–872.
   PubMed Web of Science ®Google Scholar
• Lee SR, Park EW, Cheong YS, et al. Patient's perspective of common cold and health care utilization. Korean J Fam Med. 2009;30(6):440–448.
   Google Scholar